Cargando…
Canakinumab in a subgroup of patients with COVID-19
Autores principales: | Ucciferri, Claudio, Auricchio, Antonio, Di Nicola, Marta, Potere, Nicola, Abbate, Antonio, Cipollone, Francesco, Vecchiet, Jacopo, Falasca, Katia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272172/ https://www.ncbi.nlm.nih.gov/pubmed/32835251 http://dx.doi.org/10.1016/S2665-9913(20)30167-3 |
Ejemplares similares
-
Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
por: Katia, Falasca, et al.
Publicado: (2021) -
Parameters associated with diagnosis of COVID‐19 in emergency department
por: Ucciferri, Claudio, et al.
Publicado: (2021) -
Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
por: Ucciferri, Claudio, et al.
Publicado: (2022) -
Role of monoclonal antibody drugs in the treatment of COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020) -
Molnupiravir as an Early Treatment for COVID-19: A Real Life Study
por: Pontolillo, Michela, et al.
Publicado: (2022)